创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels: Characteristics of CD34+ HSC Mouse Model

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-04 14:27
  • Views:

(Summary description)With the rapid development of life science, animal models play an increasingly important role in biomedical research. Among them, the CD34+ HSC mouse model launched by InnoModels Biotechnology provides researchers with an efficient and reliable experimental tool by virtue of its unique advantages. In this article, we will introduce the features of the CD34+ HSC model of InnoModels Biotechnology in detail

InnoModels: Characteristics of CD34+ HSC Mouse Model

(Summary description)With the rapid development of life science, animal models play an increasingly important role in biomedical research. Among them, the CD34+ HSC mouse model launched by InnoModels Biotechnology provides researchers with an efficient and reliable experimental tool by virtue of its unique advantages. In this article, we will introduce the features of the CD34+ HSC model of InnoModels Biotechnology in detail

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-04 14:27
  • Views:
Information

With the rapid development of life science, animal models play an increasingly important role in biomedical research. Among them, the CD34+ HSC mouse model launched by InnoModels Biotechnology provides researchers with an efficient and reliable experimental tool by virtue of its unique advantages. In this article, we will introduce the features of the CD34+ HSC model of InnoModels Biotechnology in detail.
Model Overview:
The CD34+ HSC mouse model is an animal model expressing human CD34+ hematopoietic stem cells (Hematopoietic Stem Cells, HSCs) successfully constructed by InnoModels Biotechnology using advanced gene editing technology in mice. This model can mimic part of the function of the human hematopoietic system, which provides powerful support for the study of blood diseases, drug screening and regenerative medicine.
Model features:
1. Highly simulate the human hematopoietic system: the hematopoietic stem cells in the CD34+ HSC mouse model have a high potential for self-renewal and differentiation, and are able to mimic the physiological and pathological processes of the human hematopoietic system, which provides an important basis for the study of the pathogenesis and therapeutic strategies of blood diseases.
2. High stability: CD34+ expression in mouse hematopoietic stem cells achieved by gene editing technology is highly stable, and can maintain stable genetic characteristics in multiple generations of mice, ensuring the reliability and reproducibility of experimental results.
3. Easy to operate: The model mice are relatively simple to feed and manage, and the experiments are easy to operate, which is suitable for various experimental techniques, such as flow cytometry and microscopic observation.
4. Wide application prospects: The CD34+ HSC mouse model has wide application prospects in the fields of blood disease research, drug screening, regenerative medicine and immunology. Through this model, researchers can deeply study the biological characteristics of hematopoietic stem cells and provide new ideas and methods for the treatment of blood diseases.


Application fields:
1. blood disease research: using the CD34+ HSC mouse model, researchers can simulate the pathogenesis of various blood diseases, such as leukemia, anemia, etc., so as to study the pathogenesis of these diseases in depth, and provide strong support for the search of effective treatment methods.
2. Drug Screening: The model can be used as an important tool for drug screening, providing an important reference for drug development by evaluating the efficacy of different drugs in the model mice.
3. Regenerative medicine: CD34+ HSC mouse models provide an important experimental platform for regenerative medicine. Researchers can use these mice models for hematopoietic stem cell transplantation, tissue engineering and other studies, providing new possibilities for future medical treatments.
Summary:
By virtue of its high simulation of the human hematopoietic system, stability, ease of operation, and wide range of application prospects, the InnoModels Biotechnology CD34+ HSC mouse model opens up a new path for biomedical research. With the in-depth study of this model by researchers, it is believed that more breakthroughs will be achieved in the future in the fields of blood disease treatment, drug screening and regenerative medicine.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司